Sylvester Comprehensive Cancer Center

  • 20201218 - Civantos Jr Francisco

  • Investigator:
    Francisco Civantos Jr
    RCname Email

    Coordinator:

    IRB: 20201218

    SDG: Head and Neck
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer

    Eligibility Criteria - NCT04333537 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201539 - Franzmann Elizabeth

  • Investigator:
    Elizabeth Franzmann
    RCname Email

    Coordinator:
    RCemailImg Zaida Abreu
    RCphone +1 (305) 2434243

    IRB: 20201539

    SDG: Head and Neck
    Disease Site(s):

    Multiple

    Sponsor: Aveta Biomics

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    An exploratory study to evaluate the safety and effectiveness of APG-157 as neo-adjuvant/Induction therapy for patients with head and neck squamous cell cancer (HNSCC) of the oral cavity

    Eligibility Criteria - NCT05312710 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221112 - Franzmann Elizabeth

  • Investigator:
    Elizabeth Franzmann
    RCname Email

    Coordinator:

    IRB: 20221112

    SDG: Head and Neck
    Disease Site(s):

    Lip, Oral Cavity and Pharynx

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    Phase II A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

    Eligibility Criteria - NCT05865028 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221146 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20221146

    SDG: Head and Neck
    Disease Site(s):

    Multiple

    Sponsor: BioNTech SE

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester
    UMH

    Title:

    An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is posi

    Eligibility Criteria - NCT04534205 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230991 - Ikpeazu Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20230991

    SDG: Head and Neck
    Disease Site(s):

    Multiple

    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

    Eligibility Criteria - NCT05063552 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210783 - Nicolli Elizabeth

  • Investigator:
    Elizabeth Nicolli
    RCname Email

    Coordinator:

    IRB: 20210783

    SDG: Head and Neck
    Disease Site(s):

    Multiple

    Sponsor: ECOG

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

    Eligibility Criteria - NCT04671667 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230134 - Olazagasti Coral

  • Investigator:
    Coral Olazagasti
    RCname Email

    Coordinator:

    IRB: 20230134

    SDG: Head and Neck
    Disease Site(s):

    Multiple

    Sponsor: NRG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Protocol NRG-HN009, Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head

    Eligibility Criteria - NCT05050162 *This information has been extracted from " www.clinicaltrials.gov"